Tower Research Capital (TRC)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,091
| Closed | -$2.9K | – | 6177 |
|
|
2024
Q1 | $2.9K | Sell |
1,091
-9,545
| -90% | -$23.6K | ﹤0.01% | 4968 |
|
|
2023
Q4 | $25.2K | Sell |
10,636
-70
| -0.7% | -$124 | ﹤0.01% | 3517 |
|
|
2023
Q3 | $15K | Sell |
10,706
-811
| -7% | -$1.95K | ﹤0.01% | 3642 |
|
|
2023
Q2 | $34.9K | Buy |
11,517
+8,423
| +272% | +$32.5K | ﹤0.01% | 2886 |
|
|
2023
Q1 | $20K | Buy |
3,094
+2,406
| +350% | +$14.7K | ﹤0.01% | 3464 |
|
|
2022
Q4 | $4K | Sell |
688
-6,238
| -90% | -$50.8K | ﹤0.01% | 5107 |
|
|
2022
Q3 | $83K | Buy |
6,926
+5,021
| +264% | +$65.7K | ﹤0.01% | 2724 |
|
|
2022
Q2 | $24K | Buy |
1,905
+1,117
| +142% | +$10.4K | ﹤0.01% | 3626 |
|
|
2022
Q1 | $9K | Sell |
788
-545
| -41% | -$6K | ﹤0.01% | 4516 |
|
|
2021
Q4 | $23K | Buy |
1,333
+801
| +151% | +$16.9K | ﹤0.01% | 3534 |
|
|
2021
Q3 | $12K | Sell |
532
-116
| -18% | -$2.52K | ﹤0.01% | 4187 |
|
|
2021
Q2 | $15K | Sell |
648
-2
| -0.3% | -$51 | ﹤0.01% | 4149 |
|
|
2021
Q1 | $20K | Buy |
+650
| New | +$22.6K | ﹤0.01% | 3896 |
|
Tower Research Capital (TRC)'s KNTE Position: Q2 2024 in Review
Tower Research Capital (TRC) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,091 shares — an estimated $2.9K sold.
Tower Research Capital (TRC) first reported a position in KNTE in Q1 2021 and held it in 13 quarters. The position peaked at $83K in Q3 2022. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Tower Research Capital (TRC) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,091 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $2.9K.
- Tower Research Capital (TRC) first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Kinnate Biopharma Inc. Common Stock position peaked at $83K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.